Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Abby L Klauer"'
Publikováno v:
Open Forum Infectious Diseases. 9
Background Rezafungin (RZF) is a once-weekly echinocandin (ECH) with a long half-life and front-loaded drug exposure. RZF is in development to treat candidemia and invasive candidiasis and prevent invasive fungal disease caused by Candida, Aspergillu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3326d0d48d6f6a952da511e6bdbd48c6
https://doi.org/10.1093/ofid/ofac492.1361
https://doi.org/10.1093/ofid/ofac492.1361
Autor:
Cecilia G. Carvalhaes, Abby L. Klauer, Paul R. Rhomberg, Michael A. Pfaller, Mariana Castanheira
Publikováno v:
J Clin Microbiol
Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for Candida spp. and rezafungin. The activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51515d5e8d298898e0c8d79ddab94575
https://europepmc.org/articles/PMC9020363/
https://europepmc.org/articles/PMC9020363/
Publikováno v:
Open Forum Infectious Diseases. 8:S628-S628
Background Rezafungin (RZF) is a new echinocandin (ECH) with a long half-life and front-loaded drug exposure that allow for once-weekly intravenous administration. RZF is under Phase 3 development for the treatment of candidemia and invasive candidia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77fe87d10228cb4e62446ad558028ed2
https://doi.org/10.1093/ofid/ofab466.1270
https://doi.org/10.1093/ofid/ofab466.1270